Search Bar & Filters
Found 12 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating how well a new injectable medicine called cagrilintide helps adults with excess body weight to lose weight. This phase 3 trial compares two different presentations of cagrilintide to placebo in people with overweight or obesity. The purpose is to understand the relative change in body weight from the start of treatment to the end of 26 weeks of treatment. Participants will be randomly assigned to one of three groups receiving weekly subcutaneous injections for 26 weeks one group receives cagrilintide with placebo matched to semaglutide in one device and placebo matched to cagrilintide in another another group receives cagrilintide in one device with matched placebos in the other and the last group receives matched placebos in both devices. This double-blind study uses devices for administration and treatment allocation is random. During the study, participants will have regular assessments including measurements of body weight and monitoring for adverse events from the start through 33 weeks. The main outcome measured is the relative change in body weight after 26 weeks of treatment. Safety is also monitored by counting any treatment-emergent adverse events or serious adverse events. Participants are involved for about 9 months in total.
Actively Recruiting
Researchers are evaluating the efficacy and safety of tulisokibart in people with moderately to severely active Crohns disease. This program includes two separate studies Study 1, which involves both induction and maintenance treatment phases, and Study 2, which includes only the induction treatment phase. The main goals are to see if one or more doses of tulisokibart are better than placebo in achieving clinical remission according to specific Crohns Disease Activity Index scores or stool frequency and abdominal pain scores, and to assess endoscopic response at weeks 12 and 52 depending on the study and regulatory region. Participants receive tulisokibart either intravenously or subcutaneously at different dose levels depending on the study arm. Some receive a high dose induction followed by high or low dose maintenance, others receive low dose throughout, and some receive placebo. Extension arms allow participants who complete their original treatment to continue receiving high or low dose subcutaneous tulisokibart if they qualify. The study uses random assignment to treatment groups and is double-blind, meaning neither participants nor researchers know who receives the drug or placebo. Throughout the studies, participants undergo evaluations at specified weeks to measure clinical remission, clinical response, endoscopic response, and other outcomes such as fatigue and quality of life. Safety is monitored by tracking adverse events and discontinuations due to side effects. The overall participation may last up to 52 weeks for Study 1 and 12 weeks for Study 2, with assessments at multiple points to carefully observe treatment effects and safety.
Actively Recruiting
Researchers are evaluating the effects of felzartamab in adults with Immunoglobulin A nephropathy IgAN, a kidney disease caused by the buildup of abnormal IgA antibodies in the kidneys. This buildup leads to inflammation and damage, resulting in protein in the urine proteinuria. The study aims to learn how felzartamab affects proteinuria and kidney function compared to a placebo, while also assessing the safety and how the drug is processed by the body. Participants will be randomly assigned to receive either intravenous IV infusions of felzartamab or a placebo that contains no active medicine. The treatment period lasts for 24 weeks, followed by an 80-week follow-up period. Some participants with lower kidney filtration rates will be included in specific cohorts receiving either felzartamab or placebo. Overall, participants will have 17 study visits during about 2 years in the trial. During the study, participants will undergo various assessments including urine protein measurement, kidney function tests using estimated glomerular filtration rate eGFR, and monitoring for immune responses and adverse events. Blood samples will be collected to measure drug levels and antibodies against felzartamab. Safety will be monitored through vital signs, laboratory tests, physical exams, and ECGs. Researchers will evaluate changes from baseline up to 36 weeks for proteinuria and up to 104 weeks for kidney function and safety outcomes.
Actively Recruiting
Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and established cardiovascular disease but no history of heart failure. This study aims to understand if this combination can reduce the risk of cardiovascular events compared to a placebo combined with empagliflozin. Participation is randomized and double-blinded to compare these treatments fairly. Participants are randomly assigned to one of two groups one takes vicadrostat plus empagliflozin, and the other takes placebo tablets that look like vicadrostat plus empagliflozin. They take one tablet daily for a period ranging from two and a half years up to four years and three months. All participants continue their regular medications for diabetes, hypertension, and cardiovascular disease alongside the study treatments. Throughout the study, participants attend regular visits where their health is carefully monitored. Doctors collect information about cardiovascular events and take blood samples. They also track any side effects and changes in blood pressure and kidney function. The main outcome is the time until the first cardiovascular death or heart failure event, observed over up to 51 months. Participants stay in the study for up to four years and three months with ongoing health assessments.
Actively Recruiting
Researchers are evaluating the effectiveness of a physical activity coaching intervention delivered through an eHealth platform to improve physical activity levels and health outcomes in patients with Chronic Obstructive Pulmonary Disease COPD undergoing pulmonary rehabilitation. This randomized controlled trial includes patients who are clinically stable with COPD and enrolled in a pulmonary rehabilitation program. The study aims to assess whether this coaching approach can enhance patients activity during and after the rehabilitation period. All participants will attend a 10-week pulmonary rehabilitation program consisting of 20 sessions, including exercise training, educational sessions, and counseling on topics like medication, smoking cessation, and nutrition. At the midpoint week 5 of the program, the experimental group will start receiving a personalized physical activity coaching intervention via an eHealth platform, which includes a mobile app and web app for healthcare professionals. This coaching, continuing for 6 months after rehabilitation ends, involves weekly goal setting through phone calls, personalized notifications, and support to overcome barriers to physical activity. Participants will be assessed at multiple points the start, midpoint, and end of the pulmonary rehabilitation program, and again at 3 and 6 months after its completion. Researchers will monitor daily step counts using accelerometers and evaluate exercise capacity, breathlessness, fatigue, symptom impact, quality of life, and self-efficacy for physical activity. The study includes ongoing tracking of progress and health outcomes to better understand the long-term effects of the coaching intervention.
Actively Recruiting
Researchers are evaluating whether adjusting exercise intensity to increase pleasure and arousal can improve physical activity behavior in patients who have experienced acute coronary syndrome ACS during a cardiac rehabilitation program. The study focuses on comparing physical activity levels and emotional responses between a group with exercise intensity manipulated for pleasure and a control group following a standard exercise program. This research is important because ACS patients face risks of recurrence and reduced quality of life, and promoting sustained physical activity is crucial for recovery and health. Participants will undergo sixteen personalized hospital exercise sessions, twice a week, during phase 2 of cardiac rehabilitation, alongside a complementary physical activity program integrated into daily life. The control group will follow conventional exercise guidelines based on the European Association of Preventive Cardiology principles, while the experimental group will have exercise intensity adjusted to optimize pleasurable feelings within safe intensity limits. Both groups receive pre-exercise evaluations and health briefings, and their programs last for eight weeks. During the study, participants will be assessed before and after the exercise program and again at three months follow-up. Physical activity will be measured using questionnaires and accelerometers. Researchers will also monitor emotional responses during exercise sessions, exercise habits, motivation, enjoyment, and physical health markers like body weight and abdominal circumference. These evaluations help understand how exercise intensity and pleasure influence activity levels and long-term adherence in cardiac rehabilitation.
Actively Recruiting
Researchers are studying the use of Ofatumumab in adults with Relapsing Multiple Sclerosis RMS in Portugal. The study compares patients who started Ofatumumab within three years of their RMS diagnosis to those who began treatment more than three years after diagnosis. This observational research aims to understand the effectiveness of Ofatumumab during routine medical care. Participants are divided into two groups based on the timing of their Ofatumumab treatment initiation. Data will be collected over a maximum of 24 months during three scheduled visits. If a patients disability score worsens at the 12- or 24-month visit, an additional visit will confirm this change. Patients must have started Ofatumumab within 12 months before joining the study or begin treatment at the time of inclusion. Throughout the study, patients will complete various assessments including questionnaires on MS impact, fatigue, and treatment satisfaction at baseline, 12 months, and 24 months. Researchers will measure the proportion of patients showing no evidence of disease activity NEDA-3 between months 12 and 24. The study includes monitoring treatment discontinuation and collects data under routine care conditions over two years.
Actively Recruiting
Researchers are evaluating how well seltorexant works and its safety when added to antidepressant treatment in adults and elderly participants with major depressive disorder who also experience insomnia symptoms. The study focuses on participants who have not adequately responded to treatment with selective serotonin reuptake inhibitors SSRIs or serotonin-norepinephrine reuptake inhibitors SNRIs. It aims to compare seltorexant with placebo as an additional therapy to improve depressive symptoms in this group. Participants will take seltorexant or a matching placebo orally once daily for 6 weeks during the double-blind phase of Part 1, while continuing their current SSRI or SNRI antidepressant. Those who complete Part 1 and meet criteria can enter Part 2, which includes open-label induction and stabilization phases where all receive seltorexant alongside their antidepressant. Participants who achieve a stable response then enter a double-blind maintenance phase in Part 2, receiving either seltorexant or placebo daily along with their antidepressant. During the study, participants will undergo assessments including depression rating scales like the Montgomery-Asberg Depression Rating Scale MADRS and patient-reported sleep disturbance measures. Researchers will monitor changes in depressive symptoms and sleep over time, track time to relapse during the maintenance phase, and evaluate safety. The total study duration may extend up to nearly three years for some participants, with follow-up after each treatment phase.
Actively Recruiting
Researchers are evaluating the effectiveness, safety, and lasting effects of faricimab in Caucasian patients with symptomatic macular polypoidal choroidal vasculopathy PCV. PCV is a type of choroidal vasculopathy that causes hemorrhagic and exudative macular degeneration. This study aims to see how intravitreal injections of faricimab 6 mg affect best corrected visual acuity BCVA outcomes in these patients, addressing the current unmet needs due to disease heterogeneity and treatment challenges. The study involves administering faricimab injections directly into the eye following a treat and extend regimen tailored to each patient. It is an open-label, single-arm study lasting approximately 100 weeks, including a screening period of up to 28 days, a 12-week treatment initiation period, and a subsequent treat and extend phase extending to week 100. Participants receive faricimab at intervals up to 24 weeks based on their response and the study protocol. Participants will undergo regular eye examinations, safety assessments, and visual acuity testing using the ETDRS protocol. The study will monitor changes in BCVA from baseline through weeks 40, 44, 48, and up to 104 weeks, along with imaging to assess polypoidal lesion regression and retinal thickness. Adverse events will be tracked throughout the study. Overall participation spans more than two years, allowing detailed evaluation of faricimabs effects on vision and eye health in this population.
Actively Recruiting
Researchers are evaluating whether the medicine BI 1291583 can help adults and adolescents aged 12 to under 18 who have bronchiectasis and experience flare-ups, also called exacerbations. This Phase III randomized, double-blind, placebo-controlled study aims to assess the medicines safety, tolerability, and effect on reducing flare-ups in people with this condition. Participants are randomly assigned to one of two groups. One group takes BI 1291583 tablets, and the other takes placebo tablets that look the same but contain no active medicine. They take one tablet daily for up to 76 weeks, or about 1 year and 6 months. The study includes up to 10 in-person visits and around 13 phone calls with study staff during this time. During the study, participants regularly complete a symptom diary on a smartphone about their bronchiectasis. Study doctors monitor participants health, check for flare-ups, and record any unwanted effects. The main outcome measured is the annual rate of pulmonary exacerbations up to week 76, with other assessments including lung function tests and quality of life questionnaires. Participants stay in the study for up to 1 year and 8 months in total.
1-10 of 12
1